Pemphigus Clinical Trial
Official title:
Validation of 5-Point Investigator Global Assessments for Pemphigus
This study aims to explore the reliability and validity of newly developed Investigator Global Assessments (IGAs) in scoring the severity of pemphigus. IGAs are simple 5-point scales ranging from clear - severe and are preferred by the FDA as endpoints in clinical trials.
This study aims to obtain statistical data regarding the inter-rater and intra-rater reliability of the IGAs, Pemphigus Disease Activity Index (PDAI) and Autoimmune Bullous Skin Disease Intensity Score (ABSIS) as well as the convergent validity of the IGAs with the PDAI and objective component of the ABSIS. Photograph sets of pemphigus lesions will be gathered from the lead site and participant sites. They will be de-identified and printed in a two hardcopy booklets; the first containing 20 photo sets and the second containing 17 new photo sets and 3 repeat photo sets. In the first part of the study, 8 dermatologists will score 20 sets of photographs of pemphigus lesions (a mixture of skin and mucosal lesions), using the IGAs for pemphigus as well as the PDAI and ABSIS. The first booklet will be mailed to dermatologists and they will use the booklet to score each photo set and will submit their scores in a confidential online survey. In the second part of the study, the second booklet will be sent to dermatologists in the same manner 4 weeks later, and each dermatologist will score the photo sets using the same scoring tools. It is estimated that each scoring session will take two hours to complete. Data gathered here will allow for calculation of inter-rater reliability and intra-rater reliability of the IGAs and convergent validity of the IGAs with PDAI and ABSIS. Later, a sub-study will occur to calculate minimal clinically important differences (MCID) for the IGAs and PDAI. This will involve scoring pemphigus severity of patients at Premier Specialists using PDAI and IGA scores and a Likert score to classify patients as improved, stable or deteriorated compared to previous visits. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00278642 -
Hematopoietic Stem Cell Support in Patients With Autoimmune Bullous Skin Disorders
|
Phase 1 | |
Not yet recruiting |
NCT05898308 -
Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus
|
Phase 4 | |
Terminated |
NCT01559155 -
Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid
|
||
Active, not recruiting |
NCT01974518 -
Comparative Study of Rituximab Versus Combination of Rituximab and Intravenous Cyclophosphamide in Severe Pemphigus
|
Phase 3 | |
Recruiting |
NCT05284929 -
Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population
|
||
Recruiting |
NCT05954416 -
FARD (RaDiCo Cohort) (RaDiCo-FARD)
|
||
Completed |
NCT00283712 -
Use of Infliximab for the Treatment of Pemphigus Vulgaris
|
Phase 2 | |
Not yet recruiting |
NCT06285435 -
Coagulation Activation in Patients With Pemphigus
|
||
Not yet recruiting |
NCT06454357 -
A Clinical Study of B007 in the Treatment of Pemphigus.
|
Phase 2/Phase 3 | |
Completed |
NCT01299857 -
Long-term Clinical and Biological Evaluation of Patients With Severe Forms of Pemphigus Treated by Rituximab
|
Phase 3 | |
Completed |
NCT00960713 -
The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders
|
N/A | |
Completed |
NCT00213512 -
Effect of Anti CD20 in Pemphigus Desease
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04400994 -
IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus
|
Phase 2 | |
Recruiting |
NCT02237313 -
Identification of Vulnerability Factors in the Course of Pemphigus Patients
|
N/A | |
Terminated |
NCT03075904 -
A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)
|
Phase 1/Phase 2 | |
Terminated |
NCT03762265 -
A Study of PRN1008 in Patients With Pemphigus
|
Phase 3 | |
Recruiting |
NCT02365675 -
Wound Dressings for Pemphigus and Pemphigoid
|
N/A | |
Recruiting |
NCT01338103 -
Treatment of Pemphigus Patients With Rituximab 1000mgX2 and Assessment of Immune Status Via Cylex
|
N/A | |
Active, not recruiting |
NCT00656656 -
Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus
|
Phase 2 | |
Completed |
NCT00127764 -
European Trial of Adjuvant Oral Glucocorticoid Pulse Therapy in Pemphigus
|
Phase 2/Phase 3 |